Home Tools
Log in
Cart

Search Result

Search Results for " t315i "

Targets

24

Compounds

Cat No. Product Name Synonyms Targets
T3196 GNF-7 GNF7 Bcr-Abl , ACK , AChR
GNF-7 is Bcr-Abl WT and Bcr-Abl T315I inhibitor with IC50 of 133 nM and 61 nM, respectively.
T3071 Olverembatinib GZD 824 Bcr-Abl
Olverembatinib (GZD 824) is an orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT, IC50: 0.34 nM) and Bcr-Abl(T315I, IC50: 0.68 nM).
T2429 Olverembatinib dimesylate GZD824 Dimesylate,HQP1351 Bcr-Abl
Olverembatinib dimesylate (GZD824 Dimesylate) is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I).
T10800 CHMFL-ABL-121 Bcr-Abl
CHMFL-ABL-121 is a highly potent inhibitor of type II ABL kinase (IC50s: 2 nM and 0.2 nM against purified inactive ABL wt and T315I kinase protein).
T4618 BGG463 K 0859 Bcr-Abl , CDK
BGG463 (K 0859) can inhibit c-ABL-T334I, BCR-ABL and BCR-ABL-T315I variants with a 50% inhibitory concentration (IC50) of 0.25 μM, 0.09 μM and 0.590 μM, respectively.
T3068 AT9283 J-504568 Apoptosis , FLT , JAK , Bcr-Abl , Aurora Kinase , Autophagy
AT9283 (J-504568) is an effective multi-targeted inhibitor of JAK2(IC50=1.2 nM) and JAK3(IC50=1.1 nM), Aurora A, Aurora B and Abl(T315I).
T2640 Rebastinib DCC2036,DCC 2036,DCC-2036 Apoptosis , FLT , Bcr-Abl , Src
DCC-2036 (Rebastinib (DCC-2036)) is a conformational control Bcr-Abl inhibitor for Abl1(WT, IC50: 0.8 nM) and Abl1(T315I, IC50: 4 nM), also inhibits LYN, SRC, HCK, FGR, FLT3, KDR, and Tie-2, and low activity to c-Kit. Re...
T72958 BCR-ABL-IN-7 Bcr-Abl
BCR-ABL-IN-7 is a WT and T315I mutant ABL kinase inhibitor.BCR-ABL-IN-7 potently inhibits WT and T315I mutant ABL kinase activity.BCR-ABL-IN-7 can be used in chronic myelogenous leukemia (CML) research.
T63746 Vamotinib PF-114 Apoptosis , Tyrosine Kinases , Bcr-Abl
Vamotinib (PF-114) is an orally active and specific tyrosine kinase inhibitor with antiproliferative and antitumour activity.Vamotinib inhibits the phosphorylation of BCR/ABL and BCR/ABL-T315I, which promotes apoptosis. ...
T6311 Bafetinib NS-187,INNO-406 Bcr-Abl , Src , Autophagy
Bafetinib (INNO-406) (INNO-406) is an effective and specific dual Bcr-Abl/Lyn inhibitor (IC50: 5.8/19 nM), and no inhibition of the phosphorylation of the T315I mutant and less effective to c-Kit and PDGFR.
T60081 BV02 2-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-1,3-dioxoisoindoline-5-carboxylic acid Others
BV02 is an inhibitor of 14-3-3 protein-protein interactions and can be used in studies about the treatment of chronic myeloid leukemia. BV02 disrupts hematopoietic cells expressing the IM-resistant T315I mutation and the...
T64338 AKI603 AKI 603,AKI-603 Aurora Kinase
AKI603 is a novel small molecule inhibitor of Aurora kinase A (AurA)(IC50 = 12.3 nM). AKI603 is developed to overcome resistance mediated by BCR-ABL-T315I mutation. AKI603 exhibits strong anti-proliferative activity in l...
T10489 BCR-ABL-IN-2 Others
BCR-ABL-IN-2 is a BCR-ABL1 tyrosine kinase inhibitor (IC50s: 57 nM, 773 nM for ABL1 native and ABL1 T315I).
T27555 HS-438 HS 438
HS-438 inhibits imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
T2802 Nocodazole R17934,Oncodazole Apoptosis , Microtubule Associated , Bcr-Abl , Autophagy , CRISPR/Cas9
Nocodazole (Oncodazole) is a reversible inhibitor of microtubule polymerization and an inhibitor of Bcr-Abl. Nocodazole has antitumor activity, blocks the cell cycle and induces apoptosis.
T15056 DB07107 Akt
DB07107 is a potent inhibitor of drug resistant T315I mutant Bcr-Abl tyrosine kinase and a potent Akt1 inhibitor (IC50: 360 nM).
T24872 TG101114 TG 101114,TG-101114
TG101114 is the T315I mutant enzyme inhibitor that acts by exhibiting reasonable in vivo efficacy in a xenograft mouse model harboring T315I.
T24496 MPT0B002 MPT-0-B-002,MPT 0 B 002
MPT0B002 is a microtubule inhibitor that acts by downregulating T315I mutant Bcr-Abl and inducing apoptosis of imatinib-resistant chronic myeloid leukemia cells.
T69045 ON012380
ON012380 is a non-ATP-competitive Bcr-Abl inhibitor, potently inhibiting imatinib-resistant Bcr-Abl mutants such as T315I.
T64087 GZD856 formic
GZD856 formic is a potent, orally active inhibitor of PDGFRα/β and Bcr-Abl T315I, demonstrating IC50 values of 68.6 nM and 136.6 nM for PDGFRα/β, respectively, and 19.9 nM and 15.4 nM for native Bcr-Abl and the T315I mut...
T63932 BCR-ABL-IN-4
BCR-ABL-IN-4 is a BCR-ABLL inhibitor that exhibits anticancer activity.BCR-ABL-IN-4 has an inhibitory effect on cancer cell growth and is able to act on K562 cells (IC50: 0.67 nM) and BCR-ABL T315I-transfected Ba/F3 cell...
T38653 HG-7-85-01
HG-7-85-01 is a type II ATP competitive inhibitor targeting wild-type and gatekeeper mutations forms of Bcr-Abl, PDGFRα, Kit, and Src kinases. It effectively inhibits T315I mutant Bcr-Abl kinase, as well as KDR and RET k...
T68581 AP23464
AP23464 is a potent adenosine 5'-triphosphate (ATP)-based inhibitor of Src and Abl kinases, displays antiproliferative activity against a human CML cell line and Bcr-Abl-transduced Ba/F3 cells (IC(50) = 14 nM. AP23464 ab...
T11523 GZD856 PDGFR
GZD856 is an orally bioavailable PDGFRα/β inhibitor (IC50s: 68.6 and 136.6 nM) with anti-lung cancer activities.
TargetMol